$6.02
+0.26 (+4.51%)
Open$6.01
Previous Close$5.76
Day High$6.02
Day Low$5.85
52W High$18.40
52W Low$4.35
Volume—
Avg Volume4.7K
Market Cap55.69M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 13.14M | 13.93M | 11.00M |
| Net Income | -2,417,675 | -2,785,079 | -2,350,186 |
| Profit Margin | -18.4% | -20.0% | -21.4% |
| EBITDA | -3,490,436 | -4,206,535 | -3,083,781 |
| Free Cash Flow | -1,263,655 | -1,934,401 | -1,577,892 |
| Rev Growth | -4.0% | +11.1% | -5.6% |
| Debt/Equity | 0.43 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |